Ralliant (NYSE:RAL) Stock Rating Lowered by Vertical Research

Ralliant (NYSE:RAL) was downgraded by equities researchers at Vertical Research from a “buy” rating to a “hold” rating in a research report issued on Wednesday, MarketBeat Ratings reports. They currently have a $65.00 price objective on the stock. Vertical Research’s price target indicates a potential upside of 4.77% from the stock’s current price.

A number of other equities research analysts have also recently commented on the company. Citigroup raised their price objective on Ralliant from $51.00 to $70.00 and gave the company a “buy” rating in a research note on Wednesday, May 13th. Wall Street Zen raised Ralliant from a “hold” rating to a “buy” rating in a research report on Saturday. Morgan Stanley lifted their target price on Ralliant from $45.00 to $68.00 and gave the company an “overweight” rating in a research report on Thursday, May 14th. Truist Financial reaffirmed a “buy” rating and set a $68.00 target price (up from $53.00) on shares of Ralliant in a research report on Wednesday, May 13th. Finally, Royal Bank Of Canada lifted their target price on Ralliant from $47.00 to $64.00 and gave the company a “sector perform” rating in a research report on Wednesday, May 13th. Six research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $64.50.

Ralliant Trading Up 0.8%

Shares of Ralliant stock opened at $62.04 on Wednesday. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.05 and a current ratio of 1.61. Ralliant has a 52 week low of $37.27 and a 52 week high of $62.95. The stock has a 50 day moving average price of $47.64 and a two-hundred day moving average price of $48.37. The stock has a market capitalization of $6.94 billion and a PE ratio of -5.67.

Ralliant (NYSE:RAL) last announced its quarterly earnings data on Tuesday, May 12th. The company reported $0.57 EPS for the quarter, beating analysts’ consensus estimates of $0.49 by $0.08. Ralliant had a positive return on equity of 12.49% and a negative net margin of 58.55%.The firm had revenue of $534.60 million during the quarter. Ralliant’s revenue was up 11.0% compared to the same quarter last year. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. As a group, equities analysts anticipate that Ralliant will post 2.64 earnings per share for the current fiscal year.

Insider Activity

In related news, SVP Karen M. Bick sold 5,485 shares of Ralliant stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $45.00, for a total transaction of $246,825.00. Following the transaction, the senior vice president owned 46,756 shares of the company’s stock, valued at $2,104,020. The trade was a 10.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Danske Bank A S purchased a new position in Ralliant in the fourth quarter worth $25,000. V Square Quantitative Management LLC purchased a new position in Ralliant in the fourth quarter worth $26,000. Allworth Financial LP boosted its position in Ralliant by 134.4% in the fourth quarter. Allworth Financial LP now owns 511 shares of the company’s stock worth $26,000 after purchasing an additional 293 shares during the last quarter. Palisade Asset Management LLC purchased a new position in Ralliant in the third quarter worth $26,000. Finally, UMB Bank n.a. purchased a new position in Ralliant in the third quarter worth $29,000.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.